239 related articles for article (PubMed ID: 33846331)
21. Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer.
Xu Y; Xiang Z; Alnaggar M; Kouakanou L; Li J; He J; Yang J; Hu Y; Chen Y; Lin L; Hao J; Li J; Chen J; Li M; Wu Q; Peters C; Zhou Q; Li J; Liang Y; Wang X; Han B; Ma M; Kabelitz D; Xu K; Tu W; Wu Y; Yin Z
Cell Mol Immunol; 2021 Feb; 18(2):427-439. PubMed ID: 32939032
[TBL] [Abstract][Full Text] [Related]
22. Lysis of a broad range of epithelial tumour cells by human gamma delta T cells: involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition.
Wrobel P; Shojaei H; Schittek B; Gieseler F; Wollenberg B; Kalthoff H; Kabelitz D; Wesch D
Scand J Immunol; 2007; 66(2-3):320-8. PubMed ID: 17635809
[TBL] [Abstract][Full Text] [Related]
23. Expression of PD1 and BTLA on the CD8
Bao Y; Mo JF; Wu JY; Cao CX
Chin Med Sci J; 2019 Nov; 34(4):248-255. PubMed ID: 33906710
[No Abstract] [Full Text] [Related]
24. γδ T-cell immunotherapy for lung cancer.
Yoshida Y; Nakajima J; Wada H; Kakimi K
Surg Today; 2011 May; 41(5):606-11. PubMed ID: 21533930
[TBL] [Abstract][Full Text] [Related]
25. Bispecific Antibody PD-L1 x CD3 Boosts the Anti-Tumor Potency of the Expanded Vγ2Vδ2 T Cells.
Yang R; Shen S; Gong C; Wang X; Luo F; Luo F; Lei Y; Wang Z; Xu S; Ni Q; Xue Y; Fu Z; Zeng L; Fang L; Yan Y; Zhang J; Gan L; Yi J; Zhou P
Front Immunol; 2021; 12():654080. PubMed ID: 34040604
[TBL] [Abstract][Full Text] [Related]
26. Bortezomib enhances cytotoxicity of ex vivo-expanded gamma delta T cells against acute myeloid leukemia and T-cell acute lymphoblastic leukemia.
Story JY; Zoine JT; Burnham RE; Hamilton JAG; Spencer HT; Doering CB; Raikar SS
Cytotherapy; 2021 Jan; 23(1):12-24. PubMed ID: 33168453
[TBL] [Abstract][Full Text] [Related]
27. Naturally activated V gamma 4 gamma delta T cells play a protective role in tumor immunity through expression of eomesodermin.
He W; Hao J; Dong S; Gao Y; Tao J; Chi H; Flavell R; O'Brien RL; Born WK; Craft J; Han J; Wang P; Zhao L; Wu J; Yin Z
J Immunol; 2010 Jul; 185(1):126-33. PubMed ID: 20525896
[TBL] [Abstract][Full Text] [Related]
28. Renal Cell Carcinoma-Infiltrating CD3
Lee HW; Park C; Joung JG; Kang M; Chung YS; Oh WJ; Yeom SY; Park WY; Kim TJ; Seo SI
Curr Issues Mol Biol; 2021 May; 43(1):226-239. PubMed ID: 34071865
[TBL] [Abstract][Full Text] [Related]
29. Role of γδ T cells in α-galactosylceramide-mediated immunity.
Paget C; Chow MT; Duret H; Mattarollo SR; Smyth MJ
J Immunol; 2012 Apr; 188(8):3928-39. PubMed ID: 22412194
[TBL] [Abstract][Full Text] [Related]
30. Killing of laminin receptor-positive human lung cancers by tumor infiltrating lymphocytes bearing gammadelta(+) t-cell receptors.
Ferrarini M; Heltai S; Pupa SM; Mernard S; Zocchi R
J Natl Cancer Inst; 1996 Apr; 88(7):436-41. PubMed ID: 8618235
[TBL] [Abstract][Full Text] [Related]
31. Characteristics of Human Peripheral Blood γδ T Cells Expanded With Zoledronate.
Kim M; Kim H; Han M; Hwang HJ; Kim H; Im HJ; Kim N; Koh KN
Anticancer Res; 2021 Dec; 41(12):6031-6038. PubMed ID: 34848457
[TBL] [Abstract][Full Text] [Related]
32. Ex Vivo Expanded Human Vγ9Vδ2 T-Cells Can Suppress Epithelial Ovarian Cancer Cell Growth.
Mao TL; Miao CH; Liao YJ; Chen YJ; Yeh CY; Liu CL
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30845699
[TBL] [Abstract][Full Text] [Related]
33. γδ T cells in cancer immunotherapy.
Zou C; Zhao P; Xiao Z; Han X; Fu F; Fu L
Oncotarget; 2017 Jan; 8(5):8900-8909. PubMed ID: 27823972
[TBL] [Abstract][Full Text] [Related]
34. Gamma-delta (γδ) T cells: friend or foe in cancer development?
Zhao Y; Niu C; Cui J
J Transl Med; 2018 Jan; 16(1):3. PubMed ID: 29316940
[TBL] [Abstract][Full Text] [Related]
35. Zoledronate-activated Vγ9γδ T cell-based immunotherapy is feasible and restores the impairment of γδ T cells in patients with solid tumors.
Noguchi A; Kaneko T; Kamigaki T; Fujimoto K; Ozawa M; Saito M; Ariyoshi N; Goto S
Cytotherapy; 2011 Jan; 13(1):92-7. PubMed ID: 20831354
[TBL] [Abstract][Full Text] [Related]
36. In vitro potency, in vitro and in vivo efficacy of liposomal alendronate in combination with γδ T cell immunotherapy in mice.
Hodgins NO; Al-Jamal WT; Wang JT; Parente-Pereira AC; Liu M; Maher J; Al-Jamal KT
J Control Release; 2016 Nov; 241():229-241. PubMed ID: 27664328
[TBL] [Abstract][Full Text] [Related]
37. The depletion of DNA methyltransferase-1 and the epigenetic effects of 5-aza-2'deoxycytidine (decitabine) are differentially regulated by cell cycle progression.
Al-Salihi M; Yu M; Burnett DM; Alexander A; Samlowski WE; Fitzpatrick FA
Epigenetics; 2011 Aug; 6(8):1021-8. PubMed ID: 21725200
[TBL] [Abstract][Full Text] [Related]
38. Innate immunity to viruses: control of vaccinia virus infection by gamma delta T cells.
Selin LK; Santolucito PA; Pinto AK; Szomolanyi-Tsuda E; Welsh RM
J Immunol; 2001 Jun; 166(11):6784-94. PubMed ID: 11359837
[TBL] [Abstract][Full Text] [Related]
39. [Effect of zoledronate on the cytotoxicity of γδ T cells from PBMCs of osteosarcoma patients against osteosarcoma].
Li Z; Tang J; Sun L; Ye Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Jan; 29(1):6-9. PubMed ID: 23294710
[TBL] [Abstract][Full Text] [Related]
40. Type I IFN-mediated enhancement of anti-leukemic cytotoxicity of gammadelta T cells expanded from peripheral blood cells by stimulation with zoledronate.
Watanabe N; Narita M; Yokoyama A; Sekiguchi A; Saito A; Tochiki N; Furukawa T; Toba K; Aizawa Y; Takahashi M
Cytotherapy; 2006; 8(2):118-29. PubMed ID: 16698685
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
